| Full Name | Ahmed Fawzy |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 47 Years |
| Location | 1 Guthrie Sq, Sayre, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700861358 | NPI | - | NPPES |
| MD438980 | Other | PA | PA LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 45970 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Robert Packer Hospital | Sayre, PA | Hospital |
| Corning Hospital | Corning, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guthrie Medical Group Pc | 6002728656 | 612 |
News Archive
A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.
Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.
A study by the University of Tampere in Finland used protein profiling to find new prostate cancer mechanisms that are not shown by aberrations at the genomic level. Several new potential biomarkers of prostate cancer were also found.
A synthetic nasal formulation of the hormone oxytocin reduced caloric intake in healthy men, particularly consumption of fatty foods, after a single treatment, a new study finds. The results, to be presented Sunday at The Endocrine Society's 97th annual meeting in San Diego, confirm those of animal studies showing oxytocin reduces food intake.
› Verified 9 days ago
| Entity Name | Guthrie Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962451153 PECOS PAC ID: 6002728656 Enrollment ID: O20040301000571 |
News Archive
A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.
Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.
A study by the University of Tampere in Finland used protein profiling to find new prostate cancer mechanisms that are not shown by aberrations at the genomic level. Several new potential biomarkers of prostate cancer were also found.
A synthetic nasal formulation of the hormone oxytocin reduced caloric intake in healthy men, particularly consumption of fatty foods, after a single treatment, a new study finds. The results, to be presented Sunday at The Endocrine Society's 97th annual meeting in San Diego, confirm those of animal studies showing oxytocin reduces food intake.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ahmed Fawzy, MD 1 Guthrie Sq, Sayre, PA 18840-1625 Ph: (570) 888-5858 | Ahmed Fawzy, MD 1 Guthrie Sq, Sayre, PA 18840-1625 Ph: (570) 887-2845 |
News Archive
A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.
Myriad Genetics, Inc. today announced that it has signed an agreement with Abbott Laboratories, a global health care company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase III multi-center, multi-national clinical study of a novel drug candidate for the treatment of metastatic breast cancer.
A study by the University of Tampere in Finland used protein profiling to find new prostate cancer mechanisms that are not shown by aberrations at the genomic level. Several new potential biomarkers of prostate cancer were also found.
A synthetic nasal formulation of the hormone oxytocin reduced caloric intake in healthy men, particularly consumption of fatty foods, after a single treatment, a new study finds. The results, to be presented Sunday at The Endocrine Society's 97th annual meeting in San Diego, confirm those of animal studies showing oxytocin reduces food intake.
› Verified 9 days ago
Dr. John Thomas Sommer, M.D. Urology Medicare: Medicare Enrolled Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-887-2845 Fax: 570-887-2011 | |
Dr. Crystal Dover Sadik, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-887-2845 Fax: 570-887-2011 | |
Vineet Agrawal, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-887-2845 Fax: 570-887-2011 |